RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1229
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1200 to $1229.
June 12, 2024 | 11:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals and raises the price target from $1200 to $1229.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively impact Regeneron's stock price in the short term as it signals confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100